Loading
A National Cancer Institute effort to build a shared, blinded bank of blood samples so different multi-cancer tests can be checked on the same people.
Alliance A212102: blinded reference set for multi-cancer detection tests (NCT05334069) is an observational study sponsored by Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI). It collects blood and tissue samples from people with and without cancer to evaluate tests for early cancer detection; the official title is a blinded reference set for multicancer early detection blood tests.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,900 participants, a start on 18 August 2022 and primary completion expected on 31 January 2027.
Shares Multi-cancer early detection (MCED), National Cancer Institute (NIH), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/